DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity

Not Applicable

Recruiting

Conditions: Coronary Artery Disease
Stroke
Breast Cancer
Type2 Diabetes

Interventions: Behavioral: Attention Control (AC)
Behavioral: Progressive combine training (PCT)

First Posted Date: 2021-01-20

Last Posted Date: 2024-10-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 160

Registration Number: NCT04717050

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Feasibility of Fasting & Exercise in Pts With HR+ MBC

Not Applicable

Completed

Conditions: Breast Cancer
Metastatic Breast Cancer

Interventions: Behavioral: Prolonged Nightly Fasting
Behavioral: Exercise

First Posted Date: 2021-01-14

Last Posted Date: 2024-08-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT04708860

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Sargramostim (GM-CSF) + PD-1

Phase 2

Withdrawn

Conditions: Unresectable Melanoma
Metastatic Melanoma
Stage III Melanoma
Stage IV Melanoma

Interventions: Drug: Sargramostim (GM-CSF)
Drug: Pembrolizumab (anti-PD-1)

First Posted Date: 2021-01-11

Last Posted Date: 2023-05-22

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT04703426

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

Phase 1

Recruiting

Conditions: Peritoneal Cancer
Fallopian Tube Cancer Stage IV
Fallopian Tube Cancer
Ovarian Cancer Stage III
Fallopian Tube Cancer Stage III
Ovarian Cancer
Ovarian Cancer Stage IV

Interventions: Combination Product: Microdevice

First Posted Date: 2021-01-08

Last Posted Date: 2023-08-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT04701645

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Digitally Enhanced Smoking Cessation for High Risk Smokers

Not Applicable

Active, not recruiting

Conditions: Smoking Behaviors
Smoking Cessation
Smoking
Lung Cancer Screening
Smoking, Tobacco

Interventions: Other: Escape
Other: Standard Care

First Posted Date: 2020-12-31

Last Posted Date: 2024-07-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 153

Registration Number: NCT04691297

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

IS-free Treg HaploHCT

Phase 1

Recruiting

Conditions: Stem Cell Transplant Complications
Graft Vs Host Disease
Myeloid Leukemia, Acute
Myeloid Leukemia in Relapse (Disorder)
Myelodysplastic Syndromes

Interventions: Radiation: Radiation
Drug: Fludarabine
Drug: Thiotepa
Drug: Cyclophosphamide
Drug: Mesna
Biological: Treg-enriched donor cell
Biological: Unmodified donor T Cell
Procedure: CD34+ Haplo Peripheral Blood Stem Cell

First Posted Date: 2020-12-22

Last Posted Date: 2024-12-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT04678401

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Resilience and Equity in Aging, Cancer, and Health (REACH)

Not Applicable

Recruiting

Conditions: Colon Cancer
Esophageal Cancer
Pancreatic Cancer
Rectal Cancer
Gastrointestinal Cancer
Gastric Cancer

Interventions: Other: Phase 2 Intervention - Geriatric Co-Management

First Posted Date: 2020-12-19

Last Posted Date: 2024-03-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 257

Registration Number: NCT04674267

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Cabozantinib With Topotecan-Cyclophosphamide

Phase 1

Completed

Conditions: Relapsed Ewing Sarcoma
Refractory Ewing Sarcoma
Relapsed Osteosarcoma
Refractory Osteosarcoma

Interventions: Drug: Cabozantinib
Drug: Topotecan
Drug: Cyclophosphamide
Drug: Myeloid growth factor

First Posted Date: 2020-12-10

Last Posted Date: 2023-02-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT04661852

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Advance Care Planning: Communicating With Outpatients for Vital Informed Decision

Completed

Conditions: Communication Skills
Advance Directives
Shared Decision Making
Natural Language Processing
Advanced Care Planning
Video Decision Aids
Covid19

Interventions: Other: VitalTalk communication skills training
Other: ACP Decisions Video Program
Other: Medical Record Review

First Posted Date: 2020-12-09

Last Posted Date: 2022-07-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 42019

Registration Number: NCT04660422

Locations: 🇺🇸
Northwell Health, New Hyde Park, New York, United States

Refining Local-Regional Therapy for IBC

Not Applicable

Recruiting

Conditions: Sentinel Lymph Node
Inflammatory Breast Cancer
Breast Cancer

Interventions: Procedure: Lymphoscintigraphy

First Posted Date: 2020-11-19

Last Posted Date: 2024-12-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT04636710

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy